An Israeli soldier injured in the ongoing conflict has become a pioneer in rehabilitation, having recently completed training with the ReWalk Personal Exoskeleton, produced by Lifeward (LFWD, Financial). This achievement marks a significant milestone, as the paralyzed soldier is the first from the current war to utilize this advanced technology, enabling him to stand and walk independently.
The 25-year-old was a member of the Israel Defense Force Paratroopers Reserve Brigade when he sustained his injuries. Through the use of the ReWalk device, his experience offers a promising glimpse into the future of mobility for those with severe lower-body injuries. His personal journey has captured attention and offers hope to others facing similar challenges.
Lifeward continues to make strides in developing exoskeleton technology, exemplified by this successful deployment of the ReWalk system. The company's efforts support individuals with mobility impairments, helping them regain independence and improve their quality of life. This recent accomplishment underscores the potential impact of Lifeward's innovations in the field of medical technology.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for Lifeward Ltd (LFWD, Financial) is $8.67 with a high estimate of $13.00 and a low estimate of $3.00. The average target implies an upside of 491.58% from the current price of $1.47. More detailed estimate data can be found on the Lifeward Ltd (LFWD) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Lifeward Ltd's (LFWD, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Lifeward Ltd (LFWD, Financial) in one year is $27.68, suggesting a upside of 1789.42% from the current price of $1.465. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Lifeward Ltd (LFWD) Summary page.
LFWD Key Business Developments
Release Date: March 07, 2025
- Q4 2024 Revenue: $7.5 million, up from $6.9 million in Q4 2023.
- Full Year 2024 Revenue: $25.7 million, an 85% increase from 2023.
- AlterG Product Revenue: $5.5 million in Q4 2024, highest since acquisition in August 2023.
- ReWalk Product Revenue: $2.0 million in Q4 2024.
- Gross Margin (GAAP): 24.4% in Q4 2024, down from 35.5% in Q4 2023.
- Adjusted Gross Margin (Non-GAAP): 45.4% in Q4 2024, compared to 46.9% in Q4 2023.
- Operating Expenses (GAAP): $17.1 million in Q4 2024, up from $8.6 million in Q4 2023.
- Adjusted Operating Expenses (Non-GAAP): $6.7 million in Q4 2024, down from $7.0 million in Q4 2023.
- Operating Loss (GAAP): $15.2 million in Q4 2024, compared to $6.7 million in Q4 2023.
- Adjusted Operating Loss (Non-GAAP): $3.3 million in Q4 2024, improved from $3.8 million in Q4 2023.
- Cash and Equivalents: $6.7 million at year-end 2024, with no debt.
- 2025 Revenue Guidance: $28 million to $30 million.
- 2025 Adjusted Gross Margin Guidance: 47% to 49%.
- 2025 Non-GAAP Operating Expenses Guidance: $22 million to $23 million.
- 2025 Non-GAAP Operating Loss Guidance: $7 million to $9 million.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Lifeward Ltd (LFWD, Financial) achieved record revenue of $7.5 million in Q4 2024, marking the highest quarterly revenue in the company's history.
- The company reported an 85% increase in full-year revenue for 2024, reaching $25.7 million, demonstrating significant business scaling.
- Lifeward Ltd (LFWD) has established a Sustainable Growth Plan aimed at reducing costs and improving operating efficiency.
- The company has expanded its distribution agreement with MYOLYN, allowing for greater market penetration, particularly in the home market.
- Lifeward Ltd (LFWD) has secured a meaningful contract with BARMER in Germany, setting a standard for providing exoskeletons.
Negative Points
- The ReWalk sales were below expectations due to delays and attrition in Medicare cases, impacting revenue predictability.
- GAAP gross margin decreased to 24.4% in Q4 2024 from 35.5% in Q4 2023, primarily due to restructuring charges.
- The company recorded a $9.8 million impairment charge on intangible assets, affecting GAAP operating expenses.
- Lifeward Ltd (LFWD) received a going concern qualification from auditors, reflecting concerns about the adequacy of its balance sheet.
- The company experienced patient attrition and deferrals in the ReWalk product line, affecting sales cycles and revenue.
